Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptinyx Inc. stock logo
APTX
Aptinyx
$0.10
+3.1%
$0.08
$0.01
$0.72
N/A1.271.32 million shs231,100 shs
Chimerix, Inc. stock logo
CMRX
Chimerix
$0.90
+0.4%
$1.07
$0.88
$1.57
$79.84M1.15390,828 shs225,003 shs
CORV
Correvio Pharma
$0.42
$0.41
$0.21
$2.79
$27.80M0.085.35 million shsN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$1.70
-1.2%
$1.92
$1.24
$11.85
$32.71M1.51390,592 shs100,181 shs
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
$3.05
-1.6%
$3.84
$3.03
$7.97
$20.31M0.7722,429 shs8,002 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptinyx Inc. stock logo
APTX
Aptinyx
0.00%0.00%0.00%0.00%-22.33%
Chimerix, Inc. stock logo
CMRX
Chimerix
-1.66%-4.43%-10.00%-4.15%-22.18%
CORV
Correvio Pharma
0.00%0.00%0.00%0.00%0.00%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-3.91%-4.97%-10.88%-16.50%-84.29%
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
-4.91%-4.62%-19.69%-31.87%-36.48%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aptinyx Inc. stock logo
APTX
Aptinyx
N/AN/AN/AN/AN/AN/AN/AN/A
Chimerix, Inc. stock logo
CMRX
Chimerix
3.8562 of 5 stars
3.53.00.04.11.11.70.6
CORV
Correvio Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
1.9728 of 5 stars
3.52.00.00.00.63.30.6
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
3.9407 of 5 stars
3.03.00.04.60.80.81.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptinyx Inc. stock logo
APTX
Aptinyx
N/AN/AN/AN/A
Chimerix, Inc. stock logo
CMRX
Chimerix
3.00
Buy$8.00793.85% Upside
CORV
Correvio Pharma
N/AN/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
3.00
Buy$30.001,664.71% Upside
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
2.00
Hold$7.00129.51% Upside

Current Analyst Ratings

Latest APTX, FBIO, CORV, CMRX, and MEIP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/12/2024
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold$7.00
3/19/2024
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$5.00
3/15/2024
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
3/1/2024
Chimerix, Inc. stock logo
CMRX
Chimerix
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00
2/14/2024
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$8.00 ➝ $7.00
2/12/2024
Chimerix, Inc. stock logo
CMRX
Chimerix
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$6.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptinyx Inc. stock logo
APTX
Aptinyx
$1MN/AN/AN/A$0.57 per shareN/A
Chimerix, Inc. stock logo
CMRX
Chimerix
$320K249.51N/AN/A$2.17 per share0.41
CORV
Correvio Pharma
$32.63M0.85N/AN/A($0.02) per share-21.00
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$84.51M0.39N/AN/A$0.10 per share17.00
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
$48.82M0.42N/AN/A$3.70 per share0.82

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptinyx Inc. stock logo
APTX
Aptinyx
-$64.85M-$0.98N/AN/AN/AN/AN/AN/AN/A
Chimerix, Inc. stock logo
CMRX
Chimerix
-$82.10M-$0.92N/AN/AN/A-25,337.96%-37.93%-35.02%5/1/2024 (Confirmed)
CORV
Correvio Pharma
-$35.18M-$0.79N/AN/A-107.81%-2,128.82%-58.56%N/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$60.64M-$8.22N/AN/AN/A-74.12%-770.86%-32.87%5/20/2024 (Estimated)
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
-$31.84M$2.971.03N/AN/A39.06%39.72%18.26%5/9/2024 (Estimated)

Latest APTX, FBIO, CORV, CMRX, and MEIP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
Chimerix, Inc. stock logo
CMRX
Chimerix
-$0.21N/A+$0.21N/AN/AN/A  
3/28/2024Q4 2023
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
N/A-$0.53-$0.53-$0.53$14.46 million$19.95 million
2/29/2024Q4 2023
Chimerix, Inc. stock logo
CMRX
Chimerix
-$0.23-$0.20+$0.03-$0.20N/AN/A
2/13/2024Q2 2024
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
-$1.46-$1.66-$0.20-$1.66N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aptinyx Inc. stock logo
APTX
Aptinyx
N/AN/AN/AN/AN/A
Chimerix, Inc. stock logo
CMRX
Chimerix
N/AN/AN/AN/AN/A
CORV
Correvio Pharma
N/AN/AN/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
N/AN/AN/AN/AN/A
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptinyx Inc. stock logo
APTX
Aptinyx
N/AN/AN/A
Chimerix, Inc. stock logo
CMRX
Chimerix
N/A
10.25
10.25
CORV
Correvio Pharma
22.54
1.07
0.95
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
38.42
1.38
1.26
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
N/A
8.23
8.23

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aptinyx Inc. stock logo
APTX
Aptinyx
N/A
Chimerix, Inc. stock logo
CMRX
Chimerix
45.42%
CORV
Correvio Pharma
7.30%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
96.51%
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
52.38%

Insider Ownership

CompanyInsider Ownership
Aptinyx Inc. stock logo
APTX
Aptinyx
10.97%
Chimerix, Inc. stock logo
CMRX
Chimerix
10.00%
CORV
Correvio Pharma
N/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
33.40%
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
3.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aptinyx Inc. stock logo
APTX
Aptinyx
12N/AN/ANot Optionable
Chimerix, Inc. stock logo
CMRX
Chimerix
7289.21 million80.29 millionOptionable
CORV
Correvio Pharma
13366.19 millionN/AOptionable
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
18719.24 million12.81 millionOptionable
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
466.66 million6.40 millionOptionable

APTX, FBIO, CORV, CMRX, and MEIP Headlines

SourceHeadline
MEI Pharma (NASDAQ:MEIP) Research Coverage Started at StockNews.comMEI Pharma (NASDAQ:MEIP) Research Coverage Started at StockNews.com
americanbankingnews.com - April 21 at 2:14 AM
5 Cheap Penny Stocks to Buy According to Analysts5 Cheap Penny Stocks to Buy According to Analysts
insidermonkey.com - April 18 at 12:16 AM
MEI Pharma shelves plans for a second return of capitalMEI Pharma shelves plans for a second return of capital
msn.com - April 11 at 6:20 PM
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
businesswire.com - April 11 at 8:02 AM
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer PatientsMEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
businesswire.com - April 11 at 8:00 AM
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology ForumMEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
businesswire.com - April 10 at 8:00 AM
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid LeukemiaMEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
finance.yahoo.com - March 26 at 8:50 AM
3 Pharma Stocks Outperforming the Competition3 Pharma Stocks Outperforming the Competition
stocknews.com - March 20 at 2:03 PM
MEI Pharma Inc (MEIP)MEI Pharma Inc (MEIP)
investing.com - March 3 at 3:29 PM
MEIP MEI Pharma, Inc.MEIP MEI Pharma, Inc.
seekingalpha.com - February 29 at 11:44 PM
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
businesswire.com - February 15 at 3:02 PM
Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
businesswire.com - February 15 at 1:06 PM
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational HighlightsMEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
finance.yahoo.com - February 13 at 9:33 PM
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue EstimatesMEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - February 13 at 9:33 PM
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue EstimatesMEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates
zacks.com - February 13 at 7:16 PM
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational HighlightsMEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
businesswire.com - February 13 at 5:05 PM
MEI Pharma Inc.MEI Pharma Inc.
wsj.com - February 8 at 11:05 AM
Is MEI Pharma (MEIP) Attractively Priced?Is MEI Pharma (MEIP) Attractively Priced?
finance.yahoo.com - February 8 at 11:05 AM
Acceleron PharmaAcceleron Pharma
forbes.com - January 18 at 8:00 AM
MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024
finance.yahoo.com - January 16 at 7:59 PM
MEI Pharma: Changes In Registrant S Certifying Accountant, Financial Statements And ExhibitsMEI Pharma: Changes In Registrant S Certifying Accountant, Financial Statements And Exhibits
cbonds.com - December 28 at 5:27 AM
MEI Pharma Stock (NASDAQ:MEIP), Short Interest ReportMEI Pharma Stock (NASDAQ:MEIP), Short Interest Report
benzinga.com - December 27 at 8:54 PM
MEI Pharma Stock (NASDAQ:MEIP) Dividends: History, Yield and DatesMEI Pharma Stock (NASDAQ:MEIP) Dividends: History, Yield and Dates
benzinga.com - December 27 at 8:54 PM
MEI Pharma: Amendments To Articles Of Incorporation Or Bylaws; Change In Fiscal Year, Financial Statements And ExhibitsMEI Pharma: Amendments To Articles Of Incorporation Or Bylaws; Change In Fiscal Year, Financial Statements And Exhibits
cbonds.com - December 24 at 10:39 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aptinyx logo

Aptinyx

NASDAQ:APTX
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
Chimerix logo

Chimerix

NASDAQ:CMRX
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Correvio Pharma

NASDAQ:CORV
Correvio Pharma Corp., a specialty pharmaceutical company, engages in developing therapeutics worldwide. Its portfolio of marketed brands comprise Aggrastat (tirofiban hydrochloride) for patients with acute coronary syndrome; and Brinavess (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm. The company also offers ESMOCARD and ESMOCARD LYO, a short acting beta blocker for the treatment of supraventricular tachycardia and control of the ventricular rate in patients with atrial fibrillation; Trevyent, a development stage drug/device combination product for pulmonary arterial hypertension; Xydalba, a treatment for acute bacterial skin and skin structure infections; and Zevtera/Mabelio, a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity. Correvio Pharma Corp. was incorporated in 2018 and is headquartered in Vancouver, Canada.
Fortress Biotech logo

Fortress Biotech

NASDAQ:FBIO
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
MEI Pharma logo

MEI Pharma

NASDAQ:MEIP
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.